What Types of Cancer is Navitoclax Being Studied For?
Navitoclax is being evaluated in a variety of cancers, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and small cell lung cancer (SCLC). Its effectiveness is being tested both as a monotherapy and in combination with other therapeutic agents to enhance anti-cancer activity.
